Gastric cardia adenocarcinoma microRNA profiling in Chinese patients

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 9411-9422

  Gao, Shegan ^a   Zhou, Fuyou ^b   Zhao, Chen ^c   Ma, Zhikun ^a   Jia, Ruinuo ^a   Liang, Shuo ^a   Zhang, Mengxi ^a   Zhu, Xiaojuan ^a   Zhang, Pengfei ^a   Wang, Lu ^d   Su, Feng ^d   Zhao, Jiangman ^d   Liu, Gang ^a   Peng, Bo ^d   Feng, Xiaoshan ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Oncology   (China)

^c Zhangjiang Center   (China)

^d Modern Preparation Technology of TCM   (China)

Author keywords

Differentiation; Gastric cardia adenocarcinoma; Microarray; microRNA; miR135b 5p

Indexed keywords

MICRORNA; MICRORNA 1244; MICRORNA 135B 5B; MICRORNA 3196; MICRORNA 628 3P; MICRORNA 628 5P; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CARDIA CARCINOMA; CHINESE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GASTRIC CARDIA ADENOCARCINOMA; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA ANALYSIS; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; TISSUE SECTION; UPREGULATION; ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA MICROARRAY; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; STOMACH TUMOR;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84961619030     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4824-5     Document Type: Article

References (41)

1. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–5.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. Jama. 1991;265:1287–9.
3. Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617–24.
4. Okholm C, Svendsen LB, Achiam MP. Status and prognosis of lymph node metastasis in patients with cardia cancer—a systematic review. Surg Oncol. 2014;23:140–6.
5. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.
6. Gao SG, Wang LD, Feng XS, Ma BG, Wang QM, Guo RF, et al. Expression of p53 and PCNA in intestinal metaplasia tissue adjacent to gastric cardia adenocarcinoma and in gastric cardia biopsy tissue. J Zhengzhou University. 2006;1:30–2.
7. Carr JS, Zafar SF, Saba N, Khuri FR, El-Rayes BF. Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 2013;44:143–51.
8. Lee YY, Derakhshan MH. Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med. 2013;16:358–65.
9. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14:475–88.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
11. Ghahhari NM, Babashah S. Interplay between microRNAs and wnt/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51:1638–49.
12. Xiong H, Li Q, Liu S, Wang F, Xiong Z, Chen J, et al. Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage i endometrioid endometrial carcinoma. PLoS One. 2014;9, e110163.
13. Chawla JP, Iyer N, Soodan KS, Sharma A, Khurana SK, Priyadarshni P. Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by epstein-barr virus and human papillomaviruses: with special reference to oral cancer. Oral Oncol. 2015;51:731–7.
14. Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med. 2015;109:803–12.
15. Zaravinos A. The regulatory role of microRNAs in emt and cancer. J Oncol. 2015;2015:865816.
16. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, et al. Genomic loss of mir-486 regulates tumor progression and the olfm4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011;17:2657–67.
17. Tseng CW, Lin CC, Chen CN, Huang HC, Juan HF. Integrative network analysis reveals active microRNAs and their functions in gastric cancer. BMC Syst Biol. 2011;5:99.
18. Wang Y, Feng X, Jia R, Liu G, Zhang M, Fan D, et al. Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma. Mol Genet Genomics. 2014;289:291–302.
19. Chen Z, Ma T, Huang C, Zhang L, Xu T, Hu T, et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene. 2014;533:456–7.
20. Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, et al. Mir-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-b-inhibitor alpha. PLoS One. 2014;9, e87897.
21. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, et al. Triple-negative and luminal a breast tumors: differential expression of mir-18a-5p, mir-17-5p, and mir-20a-5p. Tumour Biol. 2014;35:7733–41.
22. Zheng Q, Ye J, Cao J. Translational regulator eif2alpha in tumor. Tumour Biol. 2014;35:6255–64.
23. Stolboushkina EA, Garber MB. Eukaryotic type translation initiation factor 2: structure-functional aspects. Biochemistry Biokhimiia. 2011;76:283–94.
24. Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I, Scheuner D, et al. Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J. 2004;23:169–79.
25. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.
26. Aktas BH, Qiao Y, Ozdelen E, Schubert R, Sevinc S, Harbinski F, et al. Small-molecule targeting of translation initiation for cancer therapy. Oncotarget. 2013;4:1606–17.
27. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–44.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
29. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–41.
30. Royce ME, Osman D. Everolimus in the treatment of metastatic breast cancer. Breast Cancer. 2015;9:73–9.
31. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338:221.
32. Tan X, Liu Y, Hou J, Cao G. Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus. Onco Targets Therapy. 2015;8:313–21.
33. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. Mirna-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010;16:4289–97.
34. Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, et al. Oncomir-196 promotes an invasive phenotype in oral cancer through the nme4-jnk-timp1-mmp signaling pathway. Mol Cancer. 2014;13:218.
35. Candini O, Spano C, Murgia A, Grisendi G, Veronesi E, Piccinno MS, et al. Mesenchymal progenitors aging highlights a mir-196 switch targeting hoxb7 as master regulator of proliferation and osteogenesis. Stem Cells. 2015;33:939–50.
36. Yang G, Han D, Chen X, Zhang D, Wang L, Shi C, et al. Mir-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IkappaBalpha both in vitro and in vivo. Neuro-Oncology. 2014;16:652–61.
37. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167:847–55.
38. Pena-Chilet M, Martinez MT, Perez-Fidalgo JA, Peiro-Chova L, Oltra SS, Tormo E, et al. MicroRNA profile in very young women with breast cancer. BMC Cancer. 2014;14:529.
39. Wang B, Li J, Sun M, Sun L, Zhang X. MiRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. IUBMB life. 2014;66:371–7.
40. Rossi M, Kilpinen H, Muona M, Surakka I, Ingle C, Lahtinen J, et al. Allele-specific regulation of disc1 expression by mir-135b-5p. Eur J Hum Genet. 2014;22:840–3.
41. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.